Furthermore, the FDA have also recently (November 2024) approved Eladocagene exuparvovec-tneq (Kebilidi) for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. This evidence concerns the gene DDC and hyperinsulinemic hypoglycemia, familial, 4.